Acquired ERBB2 Amplification and Overexpression as On-Target Resistance Mechanisms to Zongertinib With Subsequent Response to Trastuzumab-Deruxtecan: A Case Report

JTO Clinical and Research Reports 2026 Open access

Read full text
Authors: D.J. McMahon, A. John, F. Kalofonou, N. M. Amin, Sarah Sarker, J. Vick, N. Yousaf, N. Tokaca, JanLukas Robertus, S. MacMahon, Sanjay Popat
DOI: 10.1016/j.jtocrr.2026.100960
Cited by: 1
References: 14

Abstract

tyrosine kinase inhibitor-antibody-drug conjugate combination therapy.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Colorectal Cancer Treatments and Studies Lung Cancer Treatments and Mutations

Publication details

Journal / source
JTO Clinical and Research Reports
Publisher
Elsevier BV
Volume
7
Issue
3
Pages
100960–100960
Publication date
23 January 2026
Language
EN